• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclacel Pharmaceuti (NQ: CYCCP )

    9.020 -0.270 (-2.91%)
    Streaming Delayed Price Updated: 3:54 PM EDT, Jul 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 701
    Open 9.020
    Bid (Size) 8.080 (1)
    Ask (Size) 9.740 (1)
    Prev. Close 9.290
    Today's Range 8.860 - 9.830
    52wk Range 5.250 - 22.05
    Shares Outstanding N/A
    Dividend Yield 6.65%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
    Lengthens Patent Exclusivity of Plogosertib until August 2040 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
    From Cyclacel
    Via GlobeNewswire

    Performance

    YTD
    -45.30%
    -45.30%
    1 Month
    +16.54%
    +16.54%
    3 Month
    -48.90%
    -48.90%
    6 Month
    -54.44%
    -54.44%
    1 Year
    -35.57%
    -35.57%

    More News

    Read More
    Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Reverse Stock Split
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.